Network meta analysis of first-line therapy for advanced EGFR mutation positive non-small-cell lung cancer: updated overall survival

被引：6
作者：
Farris, M. S. [1 ]
Larkin-Kaiser, K. A. [1 ]
Scory, T. [1 ]
Boyne, D. [2 ]
Wilner, K. D. [3 ]
Pastel, M. [4 ]
Cappelleri, J. C. [5 ]
Ivanova, J. I. [4 ]
机构：
[1] Medlior Hlth Outcomes Res Ltd, Calgary, AB T2C 5P9, Canada
[2] Cytel, Toronto, ON M5J 2P1, Canada
[3] Pfizer Inc, La Jolla, CA 92121 USA
[4] Pfizer Inc, New York, NY 10017 USA
[5] Pfizer Inc, Groton, CT 06340 USA
来源：
FUTURE ONCOLOGY | 2020年 / 16卷 / 36期
关键词：
EGFRmutation positive; EGFR; network meta analysis; non-small-cell lung cancer; overall survival; tyrosine kinase inhibitors; TKI; OPEN-LABEL; SYSTEMATIC REVIEWS; PHASE-III; CHEMOTHERAPY; ERLOTINIB; AFATINIB; NSCLC; METAANALYSES; STATEMENT; GEFITINIB;
D O I：
10.2217/fon-2020-0541
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Aim:To update overall survival (OS) results from a previous network meta analysis comparing the relative clinical efficacy of epidermal growth factor receptor-targeted tyrosine kinase inhibitors (EGFRTKIs) forEGFRmutation positive (EGFR+) advanced non-small-cell lung cancer (NSCLC).Materials & methods:A Bayesian network meta analysis was conducted using updated/mature randomized controlled trial OS results in response to first-lineEGFRTKI therapies.Results:Dacomitinib showed a numerical improvement of OS relative to otherEGFRTKIs: afatinib (hazard ratio [HR] 0.87; 95% credible interval [CrI]: 0.61-1.24), erlotinib (HR: 0.79; 95% CrI: 0.44-1.42), gefitinib (HR: 0.75; 95% CrI: 0.59-0.95) and osimertinib (HR: 0.94; 95% CrI: 0.68-1.29).Conclusion:Dacomitinib should be considered as a first-line treatment option for patients diagnosed with advancedEGFR+ NSCLC.
引用
收藏
页码：3107 / 3116
页数：10
相关论文
共 36 条
  • [1] [Anonymous], 2016, LUNG CANC STAG TYP G
  • [2] [Anonymous], 1996, Bugs 0.5: Bayesian inference using Gibbs sampling, manual (version ii)
  • [3] Tyrosine kinase inhibitor combination therapy in first-line treatment of non-small-cell lung cancer: systematic review and network meta-analysis
    Batson, Sarah
    Mitchell, Stephen A.
    Windisch, Ricarda
    Damonte, Elisabetta
    Munk, Veronica C.
    Reguart, Noemi
    [J]. ONCOTARGETS AND THERAPY, 2017, 10 : 2473 - 2482
  • [4] Graphical Tools for Network Meta-Analysis in STATA
    Chaimani, Anna
    Higgins, Julian P. T.
    Mavridis, Dimitris
    Spyridonos, Panagiota
    Salanti, Georgia
    [J]. PLOS ONE, 2013, 8 (10):
  • [5] Systematic review and network meta-analysis of first-line therapy for advanced EGFR-positive non-small-cell lung cancer
    Franek, Jacob
    Cappelleri, Joseph C.
    Larkin-Kaiser, Kelly A.
    Wilner, Keith D.
    Sandin, Rickard
    [J]. FUTURE ONCOLOGY, 2019, 15 (24) : 2857 - 2871
  • [6] Oncogenic drivers, targeted therapies, and acquired resistance in non-small-cell lung cancer
    Gower, Arjan
    Wang, Yisong
    Giaccone, Giuseppe
    [J]. JOURNAL OF MOLECULAR MEDICINE-JMM, 2014, 92 (07): : 697 - 707
  • [7] First-line tyrosine kinase inhibitors in EGFR mutation-positive non-small-cell lung cancer: a network meta-analysis
    Holleman, Marscha S.
    van Tinteren, Harm
    Groen, Harry J. M.
    Al, Maiwenn J.
    Uyl-de Groot, Carin A.
    [J]. ONCOTARGETS AND THERAPY, 2019, 12 : 1413 - 1421
  • [8] The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations
    Hutton, Brian
    Salanti, Georgia
    Caldwell, Deborah M.
    Chaimani, Anna
    Schmid, Christopher H.
    Cameron, Chris
    Ioannidis, John P. A.
    Straus, Sharon
    Thorlund, Kristian
    Jansen, Jeroen P.
    Mulrow, Cynthia
    Catala-Lopez, Ferran
    Gotzsche, Peter C.
    Dickersin, Kay
    Boutron, Isabelle
    Altman, Douglas G.
    Moher, David
    [J]. ANNALS OF INTERNAL MEDICINE, 2015, 162 (11) : 777 - 784
  • [9] Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107, 10.3322/caac.21492]
  • [10] A network meta-analysis of nonsmall-cell lung cancer patients with an activating EGFR mutation: Should osimertinib be the first-line treatment?
    Lin, Jia-Zhou
    Ma, Song-Kun
    Wu, Sheng-Xi
    Yu, Shu-Han
    Li, Xu-Yuan
    [J]. MEDICINE, 2018, 97 (30)
1234